Reduced liver cancer mortality with regular clinic follow‐up among patients with chronic hepatitis B: A nationwide cohort study

Shim, Jae‐Jun; Kim, Gi‐Ae; Oh, Chi Hyuk; Kim, Jung Wook; Myung, Jisun; Kim, Byung-Ho; Oh, In‐Hwan

doi:10.1002/cam4.3421

Cited by 7 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, after adjusting for competing risk factors, the estimated 10‐year cumulative liver cancer incidence and mortality rates were 6.3% and 5.0%, respectively, which were significantly lower than the 11% and 8.9% calculated using the Kaplan–Meier method. Our results were within the range of the annual liver cancer incidence (0.01%–1.4%) 25 and mortality (0.04%–0.5%) reported in the previous literature 26–28 …”

Section: Discussionsupporting

confidence: 88%

Risk‐stratified approach by aMAP score for community population infected with hepatitis B and C to guide subsequent liver cancer screening practice: A cohort study with 10‐year follow‐up

He,

Wu,

Jia

et al. 2023

Journal of Viral Hepatitis

View full text Add to dashboard Cite

The aim of this study was to determine whether the age‐Male‐ALBI‐Platelet (aMAP) score is applicable in community settings and how to maximise its role in risk stratification. A total of thousand five hundred and three participants had an aMAP score calculated at baseline and were followed up for about 10 years to obtain information on liver cancer incidence and death. After assessing the ability of aMAP to predict liver cancer incidence and death in terms of differentiation and calibration, the optimal risk stratification threshold of the aMAP score was explored, based on absolute and relative risks. The aMAP score achieved higher area under curves (AUCs) (almost all above 0.8) within 10 years and exhibited a better calibration within 5 years. Regarding absolute risk, the risk of incidence of and death from liver cancer showed a rapid increase after an aMAP score of 55. The cumulative incidence (5‐year: 8.3% vs. 1.3% and 10‐year: 20.9% vs. 3.6%) and mortality (5‐year: 6.7% vs. 1.1% and 10‐year: 17.5% vs. 3.1%) of liver cancer in individuals with an aMAP score of ≥55 were significantly higher than in those with a score of <55 (Grey's test p < .001). In terms of relative risk, the risk of death from liver cancer surpassed that from other causes after an aMAP score of ≥55 [HR = 1.38(1.02–1.87)]. Notably, the two types of death risk had opposite trends between the subpopulation with an aMAP score of ≥55 and < 55. To conclude, this study showed the value of the aMAP score in community settings and recommends using 55 as a new risk stratification threshold to guide subsequent liver cancer screening.

show abstract

Section: Discussionsupporting

confidence: 88%

Risk‐stratified approach by aMAP score for community population infected with hepatitis B and C to guide subsequent liver cancer screening practice: A cohort study with 10‐year follow‐up

He,

Wu,

Jia

et al. 2023

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…Despite improvements in diagnosis and treatment, cancer is still burdened disease globally with the increased new cases and deaths over the years [1,2]. Annual screening and earlier detection are crucial strategies that help to reduce cancer incidence and mortality [3][4][5][6][7]. Moreover, early detection of cancers leads to the use of less-aggressive interventions that improve patients' quality of life.…”

Section: Introductionmentioning

confidence: 99%

The Diagnostic Power of Circulating miR-1246 in Screening Cancer: An Updated Meta-analysis

Khanh

Phan

et al. 2023

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Background. MicroRNA-1246 (miR-1246), an oncomiR that regulates the expression of multiple cancer-related genes, has been attracted and studied as a promising indicator of various tumors. However, diverse conclusions on diagnostic accuracy have been shown due to the small sample size and limited studies included. This meta-analysis is aimed at systematically assessing the performance of extracellular circulating miR-1246 in screening common cancers. Methods. We searched the PubMed/MEDLINE, Web of Science, Cochrane Library, and Google Scholar databases for relevant studies until November 28, 2022. Then, the summary receiver operating characteristic (SROC) curves were drawn and calculated area under the curve (AUC), diagnostic odds ratio (DOR), sensitivity, and specificity values of circulating miR-1246 in the cancer surveillance. Results. After selection and quality assessment, 29 eligible studies with 5914 samples (3232 cases and 2682 controls) enrolled in the final analysis. The pooled AUC, DOR, sensitivity, and specificity of circulating miR-1246 in screening cancers were 0.885 (95% confidence interval (CI): 0.827-0.892), 27.7 (95% CI: 17.1-45.0), 84.2% (95% CI: 79.4-88.1), and 85.3% (95% CI: 80.5-89.2), respectively. Among cancer types, superior performance was noted for breast cancer ( AUC = 0.950 , DOR = 98.5 ) compared to colorectal cancer ( AUC = 0.905 , DOR = 47.6 ), esophageal squamous cell carcinoma ( AUC = 0.757 , DOR = 8.0 ), hepatocellular carcinoma ( AUC = 0.872 , DOR = 18.6 ), pancreatic cancer ( AUC = 0.767 , DOR = 12.3 ), and others ( AUC = 0.887 , DOR = 27.5 , P = 0.007 ). No significant publication bias in DOR was observed in the meta-analysis (funnel plot asymmetry test with P = 0.652 ; skewness value = 0.672 , P = 0.071 ). Conclusion. Extracellular circulating miR-1246 may serve as a reliable biomarker with good sensitivity and specificity in screening cancers, especially breast cancer.

show abstract

“…It has been suggested that regular follow-up improves patient prognosis. 6 Clinically, αfetoprotein (AFP) and other potential biomarkers are examined in liver cancer patients every 2 years or more frequently after treatments. Moreover, computed tomography (CT), ultrasonography, or positron emission tomography-CT is suggested for regular evaluation.…”

Section: Introductionmentioning

confidence: 99%

“…A routine follow‐up plan is vital in liver cancer. It has been suggested that regular follow‐up improves patient prognosis 6 . Clinically, α‐fetoprotein (AFP) and other potential biomarkers are examined in liver cancer patients every 2 years or more frequently after treatments.…”

Section: Introductionmentioning

confidence: 99%

A novel prognostic time window based on conditional survival and outcomes analyses of primary liver cancer patients

Hong

Qiu

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

BackgroundLiver cancer is one of the most deadly and prevalent cancers. A routine follow‐up plan for liver cancer is crucial but limited. In the present study, we aimed to disclose possible risk factors and critical survival time windows for primary liver cancer.MethodsWe enrolled 692 liver cancer patients from Sun Yat‐sen University Cancer Center (SYSUCC). Univariate and multivariate logistic regression analyses of cirrhosis and recurrence were conducted. A meta‐analysis was utilized to validate an indication of creatinine (CRE) in recurrence. Conditional survival analysis was performed using the Kaplan–Meier method. The results were further verified by the SYSUCC validation cohort and Surveillance, Epidemiology, and End Results (SEER) validation cohort.ResultsOur results indicated that A/G, history of hepatitis, history of alcohol consumption and platelet (PLT) might be potential prognostic factors for cirrhosis in liver cancer patients. CRE was significantly correlated with recurrence due to various therapies, especially after transarterial embolization. Moreover, 1.5 years to 2 years may be a critical time window for deterioration in survival rate based on the conditional survival analysis.ConclusionA/G, history of hepatitis, alcohol consumption and PLT may be potential prognostic factors for cirrhosis in liver cancer patients. More attention should be focused on the renal function when treating the patients due to the significant role of CRE. 1.5 years to 2 years is a critical time window for deterioration in survival rate for liver cancer patients that contributes to determining the optimal follow‐up plan in the future.

show abstract

Reduced liver cancer mortality with regular clinic follow‐up among patients with chronic hepatitis B: A nationwide cohort study

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 7 publications

References 36 publications

Risk‐stratified approach by aMAP score for community population infected with hepatitis B and C to guide subsequent liver cancer screening practice: A cohort study with 10‐year follow‐up

Risk‐stratified approach by aMAP score for community population infected with hepatitis B and C to guide subsequent liver cancer screening practice: A cohort study with 10‐year follow‐up

The Diagnostic Power of Circulating miR-1246 in Screening Cancer: An Updated Meta-analysis

A novel prognostic time window based on conditional survival and outcomes analyses of primary liver cancer patients

Contact Info

Product

Resources

About